source
- Zealand Pharma shares tumble 12% after Boehringer obesity drug trial meets endpoints but disappoints analystsA phase 3 trial of Boehringer Ingelheim's dual‑agonist drug survodutide in people with obesity and type 2 diabetes was presented at the European Association for the Study of Diabetes meeting in Mil…
- HHS unveils ARPA-H SURPASS program to accelerate clinical trial designOn Oct 1, 2026 the U.S. Department of Health and Human Services announced a new initiative under the Advanced Research Projects Agency for Health. The initiative, named the Simulation-augmented, R…